Nanobiotix S.A. (NBTX) Form 6-K — May 21, 2026
Nanobiotix has priced an oversubscribed €85 million (approximately $98.6 million) global follow-on offering to fund its late-clinical stage operations and extend its cash runway into 2029. The offering consists of 2.18 million ordinary shares and ADSs, along with 345,099 pre-funded warrants, priced at a 14.92% discount to the three-day volume weighted average price. The transaction is supported by existing shareholders including Qatar Holding LLC and Invus, with Jefferies, TD Cowen, and Stifel acting as global coordinators.
Key figures
- Gross Proceeds
- €85.0 million
- Offering Price
- $38.98 per ADS / €33.60 per Ordinary Share
- Shares Offered
- 2,184,662 Ordinary Shares/ADSs and 345,099 Pre-funded Warrants
- Pfw expiry
- May 26, 2036
- Lockup period
- 90 days
- Discount to vwap
- 14.92%
- Pfw exercise price
- €0.03
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.